Associate Vice President
Prior to joining Gilmartin Group, Claire worked at Stern Investor Relations where she partnered with public and private life sciences companies across all stages of development to implement comprehensive investor relations programs. Previously, she worked as Director of Investor Relations at Gracell Biotechnologies (acquired by AstraZeneca), supporting the company’s IR program through its $240 million IPO in January 2021.
Before transitioning into investor relations, Claire worked in equity research, covering pre-IPO companies at dedicated IPO research provider Renaissance Capital, and REITs and real estate stocks at regional asset manager Manning & Napier Advisors.
Claire holds a BSBA, Cum Laude, in Business Administration from Bucknell University.
Interesting Facts About Claire
- Grew up riding horses competitively and was a member of Bucknell’s equestrian team
- Has three dogs (two flat-coated retrievers and one corgi) and always has a lint roller on hand
- Favorite meal is brunch